Regenxbio doses first patient in diabetic retinopathy gene therapy trial
Go back to Regenxbio doses first patient in diabetic retinopathy gene therapy trial| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 8.04 +0.16 (2.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.88 | 52 Week High | $25.00 | |||
| Open | $8.03 | 52 Week Low | $7.07 | |||
| Day High | $8.22 | P/E | N/A | |||
| Day Low | $7.90 | EPS | $0.00 | |||
| Volume | 245,536 | |||||
